Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

ABSTRACT: Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2726704 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR